Whenever possible, surgical resection remains the reference treatment for both squamous cell carcinoma and adenocarcinoma of the oesophagus. Even in operable cases, however, recurrent local or regional invasion often recurs after resection, reducing five year survival to less than 25%. Several combinations of first line radiotherapy and chemotherapy have been proposed as adjuvants to surgery In most patients, dysphagia was the first sign of recurrence (n=7). Others complained of dysphonia (n=6), chest pain (n=4) or cough (n=3). Physical examination revealed palpable cervical lymph nodes as the first sign in six patients. General health status, as defined by the WHO, was good or excellent (stage 0, n= 17; stage 1, n= 14) at diagnosis of recurrent oesophageal cancer. In most patients, body weight had remained unchanged (± 15% of weight at initial diagnosis). Weight loss had exceeded 15% in only three. Recurrent local or regional invasion involving lymph nodes, the anastomoses or the gastric plasty was seen in 24 cases including two with several localisations (Table I) . Metastasis was found in six and both local or regional invasion and metastasis occurred in one. The diagnosis of recurrent postoperative oesophageal cancer was based on pathological examination of biopsy specimens in 24 cases. Imaging and the clinical course were sufficient for diagnosis in the other seven cases. The mean (SEM) delay between initial surgical resection and recurrence was 15.0 (12.6) months (range 2 to 49 months).
Radiotherapy and chemotherapy were combined in all cases. The chemotherapy protocol included cisplatin (100 mg/M2 on day 1) and continuous infusion of 5-fluorouracil (600 mg/m2/day from day 2 to day 5). Usually, a total radiotherapy dose of 60 Gy was given from anterior and posterior fields in 30 fractions with a 25 MeV linear accelerator. In eight patients, 45 Gy was given in 25 fractions. The three years (Figure) . Median survival time was 10-7 months. Taking the initial diagnosis of cancer of the oesophagus as the starting point, survival rate was 86.8% at one year, 55.6% at two years, 31.8% at three years, 19-1/% at four years, and 4-8% at five years. Median survival time was 28.6 months.
In our study, factors that showed no effect on survival rate were: initial pathological classification of the tumour (stage I+IIA+IIB, median 11-7 months; stage III, median 9.6 months), delay between initial surgical resection and recurrence (-12 months, median= 12.6 months; <12 months, median 9.4 months), patient age (-57 years, median 9.8 months; <57 years, median 11 -4 months), and the local or metastasic nature of the recurrence (local or regional invasion, median 10 months; metastasis, median 11. 8 months). Inversely, objective tumour response to treatment was found to be a factor predictive of outcome (p<0 02). Median survival time in responders was 12.9 months compared with 3.5 months in non-responders. Survival rates at one, two, and three years were 63.9, 21.3, and 7-1% respectively in responders and 18.2, 9 1, and 0% respectively in non-responders.
Discussion
This study shows that medical treatment, mainly combined chemotherapy and radiotherapy, can provide a certain improvement in terms of survival and symptomatology in a selected population of patients with recurrent cancer of the oesophagus after initial surgical resection.
The serious prognosis of oesophageal cancer is directly related to the frequency of postoperative recurrence. Longterm results in all the series in published works have been disappointing as reported median survival rarely exceeds 18-20 months and survival at five years is about 10%.4 Prognosis is better if the surgeon can achieve total curative resection, but even in these cases, five year survival is not much longer, 23 (7) the adenocarcinoma cases). The high rate of local-regional invasion can be explained by the presence of neoplasic tissue remaining after surgery.
In a large necropsy series of oesophageal cancers,7 11 patients died early in the postoperative period. Among these 11 cases, three still had residual tumoral tissue after oesophageal resection. This finding is similar to the fact that, in our series, the pathology examination showed neoplasic invasion of the resection slice. In addition, in several cases, recurrence came very early after the operation, suggesting that neoplasic tissue, left in situ, continued to develop after surgery, invading surrounding tissues. In a report of extensive lymph node dissection, the percentage of distant lymph node involvement was extremely high even in cases with tumours considered to be superficial8 as invaded lymph nodes were found in 50% of the patients classes pTl.
It seems therefore that combining radiotherapy and chemotherapy could improve the therapeutic effect on local and local-regional invasion. But, in a series of 42 patients9 who were given a combined radiochemotherapy followed by surgery protocol, recurrence developed in 16, including one oesophagus, four oesophagus and distant metastasis, and 11 with metastasis alone.
Few treatment protocols for these postoperative recurrences of oesophageal cancer have been described in published reports. Usually, radiotherapy or The population we report here, of course, does not represent all the patients we have seen for postoperative recurrence, but our inclusion criteria (age, general health, renal function, haematological or liver status) were not different from the criteria usually used in reported prospective medical or surgical series. In any case, even if we cannot state that we have improved survival in these patients, our findings would suggest that this protocol did have a beneficial effect for most of our patients. First of all, symptomatology was improved in 75% of the patients for a mean duration of more than six months (treatment period excluded). Secondly, we saw a 65% tumour response rate including 26% with complete response based on clinical or imaging criteria, or both. Finally, survival in patients with an objective response to treatment was clearly better than in nonresponders (12.9 v 3.5 months).
In conclusion, our findings show that combining chemotherapy and radiotherapy does have a beneficial symptomatic effect in patients with recurrence of squamous cell carcinoma of the oesophagus. Tolerance to such treatment is good. Its effectiveness has been shown by a noticeable improvement in symptomatology and by median survival comparable with that obtained after palliative resection. These results also emphasise the need for close follow up in patients who have had surgical resection for cancer of the oesophagus.
